Espero Biopharma

About

Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active anticoagulant (tecarfarin) for all patients who need an oral anticoagulant including a targeted patient population with major unmet need. Unlike non-monitored oral anti-coagulant (NOAC) drugs that are direct inhibitors of thrombin or Factor Xa, tecarfarin (with one Phase III completed) could be used in patients with (i) prosthetic heart valves (especially mechanical heart valves), and/or (ii) who have renal dysfunction (ESRD) and atrial fibrillation (Afib) (an orphan indication). The second drug candidate under development is budiodarone (obtained from Budiodarone, LLC*) which is an oral Phase 2 clinical-stage drug candidate that is being investigated for its potential to suppress ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs) and for the treatment of patients with refractory Af